These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38813105)
1. Time trends and regional variations in prices of anticancer medicines in China. Zhang J; Hu S; Liu X; Liu X; Zhang J; Yang C; Fang Y Front Pharmacol; 2024; 15():1397784. PubMed ID: 38813105 [TBL] [Abstract][Full Text] [Related]
2. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China. Mingge X; Jingyu W; Qi L; Zhe Z; Qing R Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066 [TBL] [Abstract][Full Text] [Related]
3. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. Rong X; Yin J; Duan S; Sun Q; Babar ZU BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722 [TBL] [Abstract][Full Text] [Related]
4. Substantial Increase in Accessibility to Essential Anticancer Medicines in Anhui, China: A Longitudinal Study. Xu R; Li S; Mu T; Xie X; Xu C; Lv X Inquiry; 2023; 60():469580231151783. PubMed ID: 36722617 [TBL] [Abstract][Full Text] [Related]
5. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348 [TBL] [Abstract][Full Text] [Related]
6. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China. Zhu Y; Wang Y; Sun X; Li X Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326 [TBL] [Abstract][Full Text] [Related]
7. Association between provincial income levels and drug prices in China over the period 2010-2017. Shi W; Wouters OJ; Liu G; Mossialos E; Yang X Soc Sci Med; 2020 Oct; 263():113247. PubMed ID: 32799026 [TBL] [Abstract][Full Text] [Related]
8. Accessibility of essential anticancer medicines for children in the Sichuan Province of China. Chen Z; Li S; Zou K; Li H; Zeng L; Lu X; Jia ZJ; Cheng G; Zhang L Front Public Health; 2022; 10():980969. PubMed ID: 36408013 [TBL] [Abstract][Full Text] [Related]
9. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848 [TBL] [Abstract][Full Text] [Related]
10. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889 [TBL] [Abstract][Full Text] [Related]
11. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study. Gao X; Yu M; Sun Y; Zhang T; Li X; Zhang L; Wang C Risk Manag Healthc Policy; 2024; 17():2201-2208. PubMed ID: 39309121 [TBL] [Abstract][Full Text] [Related]
12. Price variation among different brands of anticancer medicines available in hospital pharmacies of Nepal. Shrestha S; Poudel RS; Kc B; Poudel BK; Sapkota B; Sharma S; Khadka A J Pharm Policy Pract; 2020; 13():6. PubMed ID: 32266073 [TBL] [Abstract][Full Text] [Related]
13. Effects of the National Essential Medicine System in reducing drug prices: an empirical study in four Chinese provinces. Song Y; Bian Y; Petzold M; Li L; Yin A J Pharm Policy Pract; 2014; 7(1):12. PubMed ID: 25317336 [TBL] [Abstract][Full Text] [Related]
14. Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China. Tang Y; Liu C; Zhang X Appl Health Econ Health Policy; 2017 Feb; 15(1):57-64. PubMed ID: 27613726 [TBL] [Abstract][Full Text] [Related]
15. A comprehensive survey of cancer medicines prices, availability and affordability in Ghana. Ocran Mattila P; Biritwum RB; Babar ZU PLoS One; 2023; 18(5):e0279817. PubMed ID: 37134123 [TBL] [Abstract][Full Text] [Related]
16. The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis. Hu S; Chen C; Yuan S; Xue F; Shi L; Fang Y; Yang C Front Pharmacol; 2019; 10():950. PubMed ID: 31555135 [No Abstract] [Full Text] [Related]
17. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914 [TBL] [Abstract][Full Text] [Related]
18. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922 [TBL] [Abstract][Full Text] [Related]
19. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231 [TBL] [Abstract][Full Text] [Related]
20. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability. Li W; Lu W; Chen H; Zhang C; Wang M; Zheng F; Wu HH; Wan GW; Yang Q; Ye L BMJ Open; 2024 Apr; 14(4):e077089. PubMed ID: 38670605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]